NEW YORK--(BUSINESS WIRE)-- The premier authority in the use of advanced imaging to diagnose prostate tumors and the utilization of MRI-guided transrectal focal laser ablation for treating these tumors, Dan Sperling, MD, D.A.B.R. points to the effectiveness of this innovative, minimally invasive procedure in virtually eliminating the risk of impotence— erectile dysfunction, or incontinence– loss of bladder control, associated with traditional forms of surgery and treatment. Prostate cancer is the most common non-skin malignancy and second-leading tumor-related cause of death in men.
“The MRI-guided transrectal focal laser ablation represents a shift from radical surgery, providing effective therapy without sacrificing quality of life,” says Dr. Sperling. “It does not require in-patient surgery or anesthesia, is completed in less than an hour, and does not impact sexual activity. Unlike other similar procedures performed outside the United States, it is FDA-cleared.”
Approximately 250,000 prostate cancer cases are diagnosed annually. Dr. Sperling explains that this procedure supports a new paradigm for patients that have a Gleason score of seven and below. The Gleason score is used to grade prostate tumors.
“Laser ablation is an attractive option for patients at a time when there is a growing perception that prostate cancer is over-treated,” says Dr. Sperling. “Now, we can lower the rate of co-morbidities and recovery times while delivering effective outcomes.”
Visit www.SperlingLaserAssociates.com for appointments and information regarding reimbursement assistance.
About Dr. Sperling
Dan Sperling, MD, D.A.B.R., is the Medical Director at the New Jersey Institute of Radiology, in Carlstadt, N.J. Certified by the American Board of Radiology and licensed in New York and New Jersey, Dr. Sperling completed a fellowship in Cardiothoracic/Body Imaging with Interventions at the Albert Einstein College of Medicine at Montefiore Medical Center in N.Y. and a second fellowship in Nuclear Radiology at Northshore University Hospital. He is a pioneer in the field of MRI-guided transrectal laser ablation, a minimally invasive procedure to treat prostate tumors with virtually no risk of incontinence or impotence. Visit http://www.SperlingLaserAssociates.com, follow http://www.twitter.com/DrDanSperling, email [email protected] or call toll free 1-855-5-PROSTATE.
CONTACT:
Media:
CPR Communications
Stephanie Clark, 201-641-1911 x53
[email protected]
KEYWORDS: United States North America New Jersey New York
INDUSTRY KEYWORDS: Surgery Health Biotechnology Hospitals Medical Devices Oncology Radiology Other Health General Health
MEDIA:
| Logo |